RxDoctor Payments Data

Panagiotis Mitropoulos, DO

Dermatology · Heathrow, FLNPI 1538283502

Payments from drug & device makers

$30,968in general payments, 2019–2025

Across 916 payments — averaging $33.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • AbbVie$3K
  • Botanix SB Inc$2K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$1K
  • plus $12K from 33 others

What the payments were for

  • Consulting fees$1,4005%
  • Speaking & faculty fees$8,66328%
  • Food & beverage$20,14165%
  • Education$7652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,968 in reported general payments places this provider in the 80th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$332,318
Medicare patients
744
Services billed
4,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$351,143
Humira(Cf) PenAdalimumab24$163,579
Cosentyx Sensoready (2 Pens)Secukinumab11$81,492
JubliaEfinaconazole28$31,639
Clobetasol Propionate114$4,019
Ketoconazole194$3,326
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc161$2,827
Ammonium Lactate80$2,107
Mometasone Furoate75$1,468
Mupirocin204$1,435
Doxycycline Hyclate46$1,019
Metronidazole18$979
Triamcinolone Acetonide61$905
Minoxidil48$536
SsdSilver Sulfadiazine17$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$217$31,63928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Heathrow

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →